Interferon gamma increases survival in murine experimental cryptococcosis

Area of Science:

• Immunology
• Infectious Diseases
• Pharmacology

Background:

• Cryptococcus neoformans (C. neoformans) causes opportunistic infections, particularly in immunocompromised individuals.
• Cellular immunity is crucial for resistance against C. neoformans infections.
• Interferon gamma (IFN-gamma) is a cytokine known to modulate immune responses.

Purpose of the Study:

• To evaluate the efficacy of recombinant rat interferon gamma (IFN-gamma) in a murine model of cryptococcosis.
• To assess the impact of IFN-gamma on survival time, organ pathology, and fungal dissemination in infected mice.

Main Methods:

• Balb/c mice were infected with the Rivas strain of C. neoformans via intraperitoneal route.
• Interferon gamma (IFN-gamma) was administered at a daily dose of 10,000 IU.
• Treatment timing and fungal inoculum size were varied to assess different experimental conditions.

Main Results:

• Delayed IFN-gamma treatment (5 days post-infection with high inoculum) did not significantly alter survival.
• Early IFN-gamma treatment (initiated at infection) showed a trend towards prolonged survival, but without statistical significance.
• Simultaneous administration of IFN-gamma with a moderate fungal inoculum (3.5 x 10^5 yeasts) significantly prolonged mouse survival (p = 0.004).

Conclusions:

• Interferon gamma (IFN-gamma) efficacy in treating murine cryptococcosis is dependent on treatment timing and infection severity.
• Early or simultaneous administration of IFN-gamma can improve survival rates in mice challenged with C. neoformans.
• Further investigation into optimal IFN-gamma dosing and scheduling for cryptococcosis treatment is warranted.